



Nexstim Plc: Henri Hannula appointed as CCO

Press release, Helsinki, 2 January 2025 at 9 AM (EET)

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that Henri Hannula has been appointed as Chief Commercial Officer (CCO) of Nexstim as of January 1, 2025. Henri continues in his new role as a Nexstim management team member and reports to the CEO, Mikko Karvinen.

Henri Hannula has held key leadership positions since joining Nexstim in 2001, most recently as Vice President, Sales and Marketing.

Mikko Karvinen, CEO of Nexstim, comments: *"Henri's tireless work towards the success of Nexstim has been one notable driving force behind Nexstim's growth journey. He is passionate about our technology and further expanding its usage globally. In his new role Henri will be responsible for managing our newly formed Brainlab partnership, first in the form of leading the practical integration work, and later in managing this growth channel. With the appointment as CCO, we want to emphasize the role Henri has in our new operational environment where both developing our own unique technology further and strategic partnerships play a key role in our commercialization path. I want to thank Henri for all the hard work done over the years and wish him success in this new position."*

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com